46 results about "Advanced breast" patented technology

This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.

Fulvestrant nanosphere/microsphere and preparation method and use thereof are provided in the present invention. The carrier material of the fulvestrant nanosphere/microsphere is methoxy ended polyethylene glycol-polylactic acid block copolymer. The nanosphere/microsphere is prepared by solvent-nonsolvent method, in-liquid drying method and/or spray drying method, and has the features of high drug loading and high encapsulation efficiency, controllable release of medicine and no irritant to application site or blood vessel. The fulvestrant nanosphere/microsphere can be used to treat metastatic advanced breast cancer in post-menopausal woman.

The invention relates to a capsule containing palbociclib and a preparation method thereof, belonging to the technical field of pharmaceutical preparations. This product can be used in combination with letrozole for patients with advanced breast cancer. The capsule contains palbociclib, diluent, disintegrant and lubricant, wherein the mass ratio of palbociclib is 10% to 40%, and the mass ratio of diluent is 30% to 80%, The mass proportion of the disintegrating agent is 1%-10%, and the consumption amount of the lubricant is 0.5-5%. In addition, the present invention also discloses a method for preparing palbociclib capsules. The palbociclib capsules prepared by the method of the present invention have simple process and operation, and are particularly suitable for industrial production. The prepared The palbociclib capsule has good stability and good dissolution rate.

The invention relates to an ultra-micronized megestrol acetate in which 100% of particle sizes are smaller than or equal to 10 mu m. The invention also relates to a pharmaceutical composition containing the ultra-micronized megestrol acetate, which comprises an effective quantity of ultra-micronized megestrol acetate and medically acceptable excipient, wherein the effective quantity is 80-160 mg of ultra-micronized megestrol acetate. The pharmaceutical composition can be prepared into dispersing tablets, common tablets and capsules and used for treating advanced breast cancer, advanced endometrial carcinoma, renal carcinoma, prostatic cancer and oophoroma, and can improve the appetite and the cachexia of patients with advanced tumors.

The invention belongs to medical technology, in particular to a dispersible tablet form of anastrozole. Through a large number of clinical investigations, we have overcome the technical prejudice that anastrozole does not need to be developed into dispersible tablets in the prior art, and obtained the present invention. Clinical experiments have confirmed that the adverse reactions of the present invention are significantly reduced, and the compliance of medication is significantly improved. Obtained unexpected clinical efficacy. It has the characteristics of low production cost, stable preparation, fast absorption and high bioavailability. The invention is suitable for treating advanced breast cancer of postmenopausal women, and provides a good therapeutic drug dosage form for breast cancer patients.

The invention relates to a novel Afatinib-maleate crystal form and a preparation method thereof. Compared with a known Afatinib salt crystal form, the Afatinib-maleate crystal form provided by the invention has a plurality of improved characteristics. The invention also relates to pharmaceutical compositions containing the Afatinib-maleate crystal form, and application in preparation of drugs used for treatment of advanced non-small cell lung cancer (NSCLC) and HER2 positive advanced breast cancer.

A method of treating cancerous or benign organ disorders by selectively irradiating organ tissue with focused energy is disclosed. The method comprises the steps of: inserting an E-field probe sensor at an appropriate depth in the organ tissue, monitoring the temperature of the skin surface near the organ (if focused energy is used), placing two or more energy applicators around the organ, Set the initial power level delivered to each energy applicator, set the initial relative phase delivered to each energy applicator to focus energy on the E-field detector located in the organ tissue (if focused energy is used) , delivering energy to two or more energy applicators to selectively irradiate organ tissue and treat at least one cancerous and benign organ condition with focused energy, adjusting delivery to each energy applicator based on monitored skin temperature during treatment monitor the energy delivered to the energy applicator, measure the total energy delivered to the energy applicator during treatment and display the total energy in real time, and deliver the desired total energy dose through the energy applicator Treatment is complete upon delivery to the organ. Focused or unfocused energy can be used as a preferred energy source with a microwave energy applicator. However, any combination of energy applicators such as electromagnetic, ultrasonic, radiofrequency, and laser may be used together to form focused energy. Unfocused energy can be combined with focused energy to enhance thermotherapy. Several applications for breast cancer treatment include treatment of advanced and early breast cancer, prevention of breast cancer, and treatment of benign breast disease and ductal carcinoma in situ.

The invention belongs to the technical field of medicines, and particularly relates to a traditional Chinese medicine preparation for treating advanced breast cancer by virtue of combined chemotherapy and a preparation method of the traditional Chinese medicine preparation. The preparation is prepared from the following medicinal materials: rhizoma cyperi, fingered citron, radix pseudostellariae, deer-horn glue, placenta hominis, spatholobus suberctu, fritillary bulb, pinellia ternata, indigo naturalis and licorice root. The traditional Chinese medicine preparation has the advantages of simple prescription, exquisite drug usage and reasonable compatibility, has magical effects of soothing liver, strengthening spleen, promoting qi circulation, relieving depression, promoting blood circulation to remove stasis, clearing heat and eliminating stagnation, has an extremely targeted curative effect on combined chemotherapy of advanced breast cancer, can be used for remarkably reducing toxic or side effects generated by chemotherapy, has a remarkable curative effect for improving physical strength and immunity, and is an effective medicine for treating advanced breast cancer by virtue of combined chemotherapy.

This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and/or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.

The invention provides a late breast cancer survival probability prediction nomogram, a survival probability determination method and a patient classification method. The nomogram comprises a score scale and a plurality of prognostic variables, and the prognostic variables are classification variables and comprise a breast cancer staging variable, a breast cancer molecular typing variable, a patient disease-free recurrence time variable, a tumor load variable and a brain metastasis variable; each prognostic variable comprises a plurality of variable values, and each variable value correspondsto one score on the score scale; the nomogram also comprises a total score scale and patient survival probability variables which are continuous variables and comprise a one-year survival probabilityvariable, a two-year survival probability variable and a three-year survival probability variable, wherein each survival probability variable comprises a variable value range, and each variable valuerange has a score range corresponding to the total score scale; the development of medical science is considered, and meanwhile, the requirements of domestic patients are considered, so that the evaluation accuracy of the advanced breast cancer is improved.

The invention discloses an application of palbociclib in mucosal malignant melanoma. In particular, the present invention provides a therapeutic application of palbociclib known to treat ER+/HER2-postmenopausal advanced breast cancer in mucosal malignant melanoma. Unlike common skin malignant melanoma, the palbociclib has the very good tumor inhibition effect on multi-source mucosal malignant melanoma with a very high degree of malignancy and no definitive treatment, which fills the blank of drug treatment for mucosal malignant melanoma and has great application prospects.

The invention provides a traditional Chinese medicine composition for treating advanced breast cancer and a preparation method and application of the traditional Chinese medicine composition, and relates to the technical field of traditional Chinese medicine theory preparations. The traditional Chinese medicine composition comprises the following raw materials in parts by weight of 5-15 parts of ginseng, 20-40 parts of radix astragali, 10-30 parts of radix bupleuri, 5-15 parts of rhizoma pinelliae preparata, 10-30 parts of radix angelica sinensis, 10-30 parts of bighead atractylodes rhizomes,10-30 parts of poria cocos, 10-20 parts of thunberg fritillary bulbs, 5-15 parts of pseudobulbus cremastrae seu pleiones, 20-40 parts of fresh oyster shells, 10-30 parts of white peony roots, 10-30 parts of snakegourd fruits and 5-15 parts of prepared rhizoma arisaematis. A traditional Chinese medicine theory is used for guidance, soothing liver, regulating qi, replenishing qi to invigorate the spleen, dissipating phlegm and resolving masses are used as a treatment principle, the traditional Chinese medicine composition is used for treating advanced breast cancer (stagnation of liver qi, spleen deficiency and intermingled pathogenic phlegm and qi ), and the traditional Chinese medicine composition is mild in temperament, rigorous in compatibility, clear in pharmacodynamics substances, andnotable in clinical efficacy.

The invention relates to an application of hsacirc0003045 as a breast cancer diagnosis and/or prognosis marker. The breast cancer forms an important threat to female health, the frequency of drug resistance, metastasis and relapse of the disease is high, the prognosis condition of advanced breast cancer patients is poor, and an early diagnosis marker is of great significance for avoiding poor prognosis of the breast cancer. The invention provides the application of the hsacirc0003045 as the breast cancer diagnosis and/or prognosis marker, the expression quantity of the marker in focus tissues and para-carcinoma tissues has obvious difference, and the marker is related to poor prognosis of the breast cancer and has important detection value for clinical diagnosis and poor prognosis prevention and treatment of the breast cancer.

The invention provides a pharmaceutical composition for treating advanced breast cancer, which has synergistic active ingredients including a therapeutically effective amount of PD-1/PD-L1 inhibitor, an angiogenesis inhibitor and a microtubule inhibitor, and provides application of the pharmaceutical composition. Compared with the prior art, the invention has the following advantages: the treatment scheme of the triple medicinal composition has a good curative effect on a patient, the PFS of the patient reaches 8.1 months, and the survival benefit of the patient is obvious; the traditional Chinese medicine composition is wide in audiences and suitable for PD-L1 negative patients, analysis shows that the treatment effect of the scheme is not affected by previous immunotherapy, the treatment effect is irrelevant to immune typing, and the patient audiences are expanded; the traditional Chinese medicine composition is safe and controllable, patients receiving the treatment scheme are free of death caused by treatment side effects, serious side effects comprise neutropenia, thrombocytopenia, transaminase increase, neutropenia and the like, and the side effects are clinically accepted to be safe and controllable.